Shuanghuang Chuanku Tablets Veterinary Grade API is a multi-dosage-form active pharmaceutical ingredient supplied for downstream veterinary pharmaceutical manufacture. The term “Tablets” in the product designation identifies the solid presentation of the input material; it does not restrict the material to tablet use. The grade is released against a route-independent specification that permits formulation into tablets, injections, capsules, powders, granules, premix, and solutions. Manufacture is performed under active pharmaceutical ingredient controls aligned with ICH Q7 and veterinary GMP expectations. Finished-product marketing authorisation holders retain responsibility for route-specific validation, including sterile filtration for parenteral preparations and content-uniformity demonstration for low-dose premixes under 21 CFR Part 211 or equivalent local regulation. The manufacturer’s model designation appears on the certificate of analysis as a batch-specific grade identifier; no compendial model number is applicable.

Published industrial data for this exact product configuration is limited. The risk profile is therefore described using the same quality-by-design principles applied to botanically derived active substances under ICH Q6A. The central control problem is that a single starting material must meet the microbial, particulate, and solubility expectations of six finished-form routes. A botanical extract that is acceptable for a tablet may carry a bioburden that would overload a sterilising-grade filter in an injectable line. Consequently, the API specification includes microbiological and particle-size controls not routinely applied to single-route oral herbal powders. Each manufacturer should perform route-specific risk assessment before assigning the material to a new dosage form.

What Changes When One API Is Transferred From Tablet Granulation to Aqueous Injection?

The transfer from solid oral processing to parenteral processing shifts the controlling attributes from compressibility and blend uniformity to solubility, filterability, endotoxin load, and sub-visible particulate content. For tablet and capsule manufacture, the powder must be free-flowing and non-hygroscopic at compression humidity; for injectable manufacture, the same substance must dissolve without precipitation at pH 5.0–7.0 and pass through a 0.45 µm prefilter before the final sterilising-grade filter. A production-scale aqueous injection route typically begins with water for injection heated to 40–60 °C, followed by pH adjustment with dilute sodium hydroxide or hydrochloric acid. If activated carbon treatment is specified in the marketing authorisation, contact time should be controlled to avoid excessive marker adsorption. The solution is then filtered sequentially through 0.45 µm and 0.22 µm membranes. The filter-loading capacity must be validated with the actual formulation because polyphenolic fractions in botanical API solutions can reduce membrane throughput relative to small-molecule drug solutions.

Particle-size distribution is measured by laser diffraction using ISO 13320:2020. The release value for D90 is ≤250 µm for tablets and capsules, but a tighter D90 of ≤150 µm is applied when the material is designated for premix and granule routes because segregation risk increases with carrier-particle size mismatch. Bulk density is controlled at 0.45–0.65 g/mL; tapped density is 0.55–0.80 g/mL, giving a Carr index commonly between 15 and 25. At relative humidity above 60%, the material should be pre-dried before compression to avoid die-fill variation and picking on rotary press tooling. Moisture sorption data for the exact multi-herb composition are not published; formulators should determine a plant-specific sorption isotherm before transferring to a new manufacturing site.

For tablet development, preformulation samples are typically evaluated on an instrumented rotary press to determine compaction force-displacement profiles. In the absence of published data for this exact multi-herb API, a formulator should start with direct-compression diluents such as microcrystalline cellulose and lactose monohydrate. The compression force window of 12–20 kN given in the table is a conservative starting range for botanical extract blends at hardness values between 60 N and 120 N. Capping and lamination may occur when fines content exceeds the specification because particle-size bimodality increases elastic recovery. A pre-compression force of 2–4 kN on a rotary press can reduce capping for brittle botanical granules. Tablet hardness should be correlated with disintegration time, not used as an isolated release parameter.

Capsule filling is performed on tamping-pin or dosator-type machines. Because the API has a tapped density above 0.55 g/mL, fill weight control is generally straightforward, but low-dose capsules may require direct compression of a triturate to meet USP 905. Powder bridging in the hopper is a known failure mode when relative humidity exceeds 60%; conditioned storage at 20–25 °C and ≤50% RH is recommended. A glidant such as colloidal silicon dioxide at 0.5–1.5% w/w may be added to improve flow without exceeding the excipient compatibility envelope. The addition level should be limited because higher concentrations can reduce tablet hardness if the same blend is used for compression.

Release Specifications and Residual Impurity Boundaries for Multi-Route Release

Each batch is released against the specification summarised below. Identity and purity limits are route-independent. Microbiological limits are route-aligned but are not sufficient by themselves to meet parenteral sterility; downstream purification and sterilisation remain mandatory for injections. Residual solvent limits follow VICH GL18 and ICH Q3C. Elemental impurity limits are consistent with ICH Q3D option 1 for oral and injectable veterinary products; the exact animal species and route should be considered in the risk assessment.

Aqueous solution clarity is maintained only within a narrow pH window. At pH values above 7.5, polyphenolic marker compounds may precipitate; at pH values below 4.0, acid-labile constituents may degrade. Injectable formulations are therefore buffered at pH 5.0–7.0. Dilute phosphate buffer systems at 10–50 mM are commonly used, but the final formulation should be tested for visible and sub-visible particulates by USP 788. Solutions should be protected from direct light during processing because botanical flavonoids undergo photochemical discolouration. For short-term holding, stainless-steel or glass contact surfaces are preferred; prolonged contact with uncoated mild steel should be avoided because chelation of polyphenols with iron can generate dark particles. These constraints are operational boundaries derived from the general behaviour of polyphenol-rich botanical extracts; batch-specific confirmation is required for the Shuanghuang Chuanku material.

For oral solutions, the API is dissolved in purified water with a co-solvent system if required. The target pH is 5.0–7.0; pH adjustment should be performed with a calibrated meter after complete dissolution. The solution should be inspected against a black and white background for visible particles before filling. Sub-visible particle testing by USP 788 is required for injectables but is also useful for oral solutions to detect precipitation during accelerated stability. Light exposure should be minimised; amber glass or opaque polymer containers are preferred for long-term storage. Preservative systems containing benzyl alcohol or parabens should be tested for compatibility because botanical polyphenols can reduce preservative activity by adsorption onto particulate matter.

If Terminal Sterilisation Is Not Feasible, What Filtration and Environmental Controls Apply to the Injectable Route?

When the finished injectable cannot be terminally sterilised by moist heat at 121 °C for 15 min without unacceptable marker degradation, aseptic filtration is required. The API as supplied is not sterile; therefore the downstream manufacturer must reduce the pre-filtration bioburden to a validated level, commonly ≤10 cfu/100 mL, before the sterilising-grade filter. Membrane selection is route-critical. A 0.22 µm polyethersulfone or PVDF membrane is preferred; regenerated cellulose and nylon membranes may show early fouling with polyphenol-rich solutions. Filter integrity testing using bubble point or diffusion tests is performed before and after use, and the final product is tested for sterility by USP 71. Environmental controls for aseptic processing follow EU GMP Annex 1; critical operations are performed in ISO 14644-1 class 5 areas with surrounding class 7 areas. Holding times between dissolution and filtration should be kept short at 2–8 °C to limit microbial proliferation unless the formulation contains a validated antimicrobial preservative.

Powder and granule routes use the same API without dissolution. For premix manufacture, the API is geometrically diluted with a carrier such as lactose monohydrate or calcium carbonate using a tumble blender or ribbon blender. Carrier particle size should be matched to the API D90 to reduce segregation; blend uniformity is confirmed by stratified sampling and HPLC assay with a target relative standard deviation of ≤5.0%. Granule manufacture by high-shear wet granulation or fluid-bed granulation uses an aqueous or hydroalcoholic binder. Inlet air temperature is maintained at 55–65 °C, and granule drying is stopped at a loss on drying of 3.0–5.0%. Material stored above 60% RH should be re-dried before tablet compression, because surface moisture above 5.0% increases sticking, picking, and weight variation on rotary presses. Direct compression is feasible only when the API lot has a Carr index below 25; otherwise dry granulation or wet granulation should be used.

The API is supplied in moisture-resistant packaging. It should be stored in a cool, dry area at ≤25 °C and protected from light. Once opened, the container should be re-sealed under dry conditions and used within the assigned retest period. Exposure to direct sunlight or high humidity can alter moisture content and marker assay. No statement on shelf life beyond the manufacturer’s assigned retest date is made here; users must verify the retest date on the certificate of analysis.

The principal difference from a generic single-herb extract powder is the multi-route control strategy. A standard veterinary botanical powder may be released only on appearance, loss on drying, and total plate count; this grade adds particle size distribution, heavy metals by USP 233, residual solvents by VICH GL18, and route-specific bioburden controls. Compared with synthetic small-molecule APIs, Shuanghuang Chuanku Tablets Veterinary Grade API has a wider solubility window, a higher molecular-weight marker distribution, and greater sensitivity to alkaline pH and oxidising agents. The material should not be pre-blended with amine-based additives without compatibility testing, because polyphenolic fractions may form insoluble complexes. Unlike single-herb extracts, the product is specified for multiple finished-form routes, reducing the need for formulators to perform separate extraction and purification steps for each dosage form. Batch-specific certificate-of-analysis data should be used for release decisions; the values in this page are specification boundaries and typical process windows, not efficacy claims.